Login to Your Account

Pfizer's Hospira takeout now generating biosimilars give-backs

By Marie Powers
News Editor

Monday, August 8, 2016

Pfenex Inc. learned late Friday that it was regaining rights to PF582, its biosimilar candidate to Lucentis, according to Paul Wagner, the company's chief financial officer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription